Thank you for your inquiry. Yes we are DTC eligible. Our ticker symbol is MDCL and we are listed on the OTC Markets as a QB company. Here is a link to our all our current Edgar filings. Thank you
"I understand. I read somewhere it takes a month or two.
Thanks again!"
JohnCM
From: Stephanie Van Hassel [mailto:stephanie@medmen.com] Sent: Friday, June 8, 2018 11:07 PM To: JohnCM Subject: Re: MedMen Will Commence Trading May 29th Under Ticker Symbol "MMEN"
Hi John,
The new ticker is not DTC eligible at this moment in time.
Kind regards, Stéphanie Sent from my iPhone
On Jun 8, 2018, at 20:52, John wrote: I have your new sponsored OTC ticker. Do you happen to know if it is DTC eligible yet?
Thank you ... Good move! Reacting and staying flexible. Good sign.
MedMen Revises Executive Compensation Plans
June 08, 2018 05:02 PM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (CSE: MMEN) (“MedMen”), the country’s leading cultivator, producer and retailer of state-sanctioned cannabis, announced today that the grant units for its co-founders under its long-term incentive plan (the “LTIP”) will now vest upon achievement of certain share price goals.
Co-founder and CEO Adam Bierman and Co-founder and President Andrew Modlin will receive their LTIP units of MM Enterprises USA LLC according to the following schedule. One third of the total units will vest when the price of MedMen’s Subordinated Voting Shares reaches CA$ 10 in the open market, another third will vest when the share price reaches CA$ 15 and the final third when the share price reaches CA$ 20. The price will be determined as a 5-day VWAP in any exchange where MedMen shares are traded.
This modification to the grants under the LTIP was made to provide greater economic alignment with MedMen’s shareholders.
About MedMen
MedMen Enterprises is the preeminent cannabis company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America’s addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen employs 800 workers across the United States. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit http://www.medmen.com or follow us on Facebook, Twitter or Instagram.
Source: MedMen Enterprises
Contacts Media Contact: Daniel Yi Senior Vice President of Corporate Communications, MedMen Enterprises daniel@medmen.com or Investor Relations Contact:
From: Stéphanie Van Hassel [mailto:stephanie@medmen.com] Sent: Tuesday, June 5, 2018 1:19 PM To: John Subject: Re: MedMen Will Commence Trading May 29th Under Ticker Symbol "MMEN"
MTTPF is not a MedMen sponsored ticker. We will issue a press release with further details if/when MedMen enters the OTC market. If you have not done so already, please sign up for investor alerts on our website.
Kind regards, Stéphanie
On Tue, Jun 5, 2018 at 11:12 AM, John wrote: MTTPF
no announcement or mention on website?
Volume, but on the grey sheet.
Perhaps you are waiting for uplist to at least pink?
John
From: Stéphanie Van Hassel [mailto:stephanie@medmen.com] Sent: Sunday, May 27, 2018 3:55 PM To: undisclosed-recipients: Subject: MedMen Will Commence Trading May 29th Under Ticker Symbol “MMEN”
We are thrilled to announce that we are on track to commence trading this coming Tuesday, May 29th on the Canadian Securities Exchange (CSE) under the ticker symbol, MMEN. Additionally, we closed our concurrent financing round on Friday, May 25th, raising CAD 143.0 million at CAD 5.25 per share with a valuation of CAD 2.14 billion.
We thank you for your continued support and interest in MedMen.
Kind regards, Stéphanie
-- Stéphanie Van Hassel Head of Investor Relations C: (917) 650-8671 www.MedMen.com
CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.